Please login to the form below

Not currently logged in
Email:
Password:

Fetcroja

This page shows the latest Fetcroja news and features for those working in and with pharma, biotech and healthcare.

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

The antibiotic treats infections caused by aerobic Gram-negative bacteria. Shionogi’s novel antibiotic Fetcroja has been selected for inclusion in a pilot subscription reimbursement scheme, launched by the UK’s ... Fetcroja was launched in the UK in

Latest news

  • Shionogi’s novel antibiotic trial data published in The Lancet Shionogi’s novel antibiotic trial data published in The Lancet

    The second study, CREDIBLE-CR, evaluated Fetcroja as a treatment for a diverse range of serious Carbapenem-resistant (CR) infections. ... Fetcroja launched in the UK in September, launching as a treatment of infections caused by aerobic Gram-negative

  • Shionogi's Gram-negative antibiotic launches in the UK Shionogi's Gram-negative antibiotic launches in the UK

    Novel antibiotic is indicated for use against Gram-negative bacterial infections. Shionogi’s new antibiotic Fetcroja is now available for use in the UK for the treatment of infections caused by ... The launch of Shionogi's Fetcroja (cefiderocol) in the

  • Modest meeting sees only two drugs recommended by CHMP Modest meeting sees only two drugs recommended by CHMP

    The CHMP recommended a marketing authorisation of Japanese pharma company Shionogi’s antimicrobial drug Fetcroja (cefiderocol) for the treatment of infections caused by Gram-negative organisms in adults with limited treatment ... options. According to

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics